AN2 Therapeutics Inc.
ANTX | NASDAQ
$4.53
-$0.16 (-3.41%)
At close: Oct 30, 2026, 4:00 PM ET
$4.53
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 5:27 AM ET
Company Profile
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Key Executives
| Name | Position |
|---|---|
| Eric E. Easom | Co-Founder, Chief Executive Officer, President & Chairman of the Board |
| Josh Eizen | Chief Legal Officer, Chief Operating Officer & Corporate Secretary |
| Cameron Trenor | Chief Medical Officer |
| George Harrison Talbot FACP | Co-Founder & Senior Clinical Advisor |
| Joseph S. Zakrzewski | Co-Founder & Independent Director |
| Lucy O. Day | CFO, & Principal Financial Officer |
| Michael R. K. Alley | Co-Founder, Senior Vice President of Research Fellow & Head of Biology |
| Sanjay Chanda | Chief Development Officer |
| Sarah Williams | Vice President of Controller & Principal Accounting Officer |
| Vince Hernandez | Senior Vice President of Research & Head of Chemistry |
AN2 Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 25, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Eric E. Easom |
Contact Details
1800 El Camino Real Menlo Park,
California 94025 United States
Stock Details
| Ticker Symbol | ANTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001880438 |
| CUSIP Number | 037326105 |
| ISIN Number | US0373261058 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ANTX